中国P站

Epigenetic Modifications; Gynecologic Cancers; DNA Methylation; Histone Modifications; Tumor Microenvironment; Non-coding RNAs; Biomarkers; Epigenetic Therapies; Genomic Instability; Treatment Resistance

Introduction

Epigenetic modifications are fundamental regulators of gene expression that play a pivotal role in the pathogenesis of various cancers, including gynecologic malignancies. These dynamic alterations, which do not involve changes to the underlying DNA sequence, profoundly influence cellular behavior and contribute to the initiation and progression of these diseases. Understanding the intricate epigenetic landscape in gynecologic cancers is crucial for deciphering their complex biology and for developing effective therapeutic strategies [1].

Among the most extensively studied epigenetic mechanisms are DNA methylation and histone modifications. DNA methylation, typically occurring at CpG dinucleotides, often leads to the silencing of tumor suppressor genes when present in promoter regions. Conversely, hypomethylation can contribute to genomic instability and oncogene activation. These patterns are frequently altered in ovarian, cervical, and endometrial cancers, underscoring their significance in tumorigenesis [2].

Histone modifications, encompassing processes such as acetylation, methylation, and ubiquitination, are equally critical in governing chromatin structure and accessibility to the transcriptional machinery. Aberrant histone modification landscapes in gynecologic cancers can result in inappropriate gene expression, thereby impacting vital cellular processes that drive cancer development. The dysregulation of these modifications highlights their importance in cancer pathogenesis [3].

The tumor microenvironment (TME) is not immune to the influence of epigenetic alterations. In gynecologic cancers, epigenetic modifications in both malignant and stromal cells can significantly impact crucial aspects of the TME, including immune cell infiltration, the formation of new blood vessels (angiogenesis), and the development of resistance to therapies [4].

Beyond protein-coding genes, non-coding RNAs (ncRNAs) such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) also play substantial roles in gynecologic tumorigenesis. These ncRNAs are themselves subject to epigenetic regulation and can function as oncogenes or tumor suppressors by modulating gene expression. The interplay between epigenetic mechanisms and ncRNAs is a burgeoning area of research with therapeutic implications [5].

The identification of specific epigenetic biomarkers holds great promise for the early detection, risk stratification, and monitoring of gynecologic cancers. Notably, DNA methylation profiles derived from circulating tumor DNA (ctDNA) are emerging as powerful tools for non-invasive diagnostics, particularly for ovarian and endometrial cancers, facilitating earlier intervention and personalized treatment [6].

The therapeutic landscape for gynecologic cancers is increasingly incorporating epigenetic interventions. Several drugs targeting key epigenetic enzymes, such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), are either approved or are undergoing clinical evaluation. These epigenetic therapies aim to reverse aberrant epigenetic marks and restore normal gene expression patterns [7].

Epigenetic dysregulation is a significant contributor to genomic instability, a hallmark of cancer. In gynecologic cancers, impaired DNA methylation and histone modification can compromise DNA repair pathways, leading to an accumulation of genetic mutations and chromosomal abnormalities. Understanding this interplay is vital for the development of targeted epigenetic therapies [8].

Furthermore, the development of resistance to standard cancer treatments in gynecologic cancers is strongly linked to epigenetic reprogramming. Aberrant epigenetic changes can alter drug transporters, signaling pathways, and cell death mechanisms, ultimately rendering cancer cells less responsive to therapeutic agents. Reversing these epigenetic alterations may offer a viable strategy to overcome therapeutic resistance [9].

Finally, recognizing the heterogeneity of epigenetic landscapes within and across different subtypes of gynecologic cancers is paramount. This intra- and inter-tumor heterogeneity underscores the need for personalized approaches to epigenetic therapy. Tailoring treatment strategies based on the unique epigenetic profile of an individual patient's tumor holds the potential to enhance treatment efficacy and minimize toxicity [10].

Description

Epigenetic modifications are crucial in the development and progression of gynecologic cancers, influencing gene expression without altering the DNA sequence itself. These alterations are fundamental to understanding tumorigenesis and developing novel therapeutic strategies [1].

The primary epigenetic mechanisms involved are DNA methylation and histone modifications. DNA methylation patterns are frequently altered in ovarian, cervical, and endometrial cancers. Hypermethylation of promoter CpG islands can silence tumor suppressor genes, while hypomethylation may lead to genomic instability and oncogene activation, playing a significant role in cancer initiation and progression [2].

Histone modifications, including acetylation, methylation, and ubiquitination, dynamically regulate chromatin structure and gene accessibility. In gynecologic cancers, aberrant histone modification landscapes contribute to inappropriate gene expression, impacting critical cellular processes necessary for cancer development. The identification of specific enzymes involved offers targets for therapeutic intervention [3].

The tumor microenvironment (TME) is profoundly affected by epigenetic alterations occurring in both cancer and stromal cells within gynecologic cancers. These modifications influence key TME components such as immune cell infiltration, angiogenesis, and the development of drug resistance, suggesting epigenetic targeting as a strategy to improve treatment outcomes [4].

Non-coding RNAs (ncRNAs), such as microRNAs and long non-coding RNAs, are integral to gynecologic tumorigenesis and are themselves subject to epigenetic regulation. These ncRNAs can function as oncogenes or tumor suppressors by modulating gene expression, and their levels can be therapeutically targeted through epigenetic interventions [5].

The discovery of specific epigenetic biomarkers is revolutionizing the early detection and risk stratification of gynecologic cancers. DNA methylation profiles found in circulating tumor DNA (ctDNA) are particularly promising for non-invasive diagnostics in ovarian and endometrial cancers, enabling earlier and more personalized treatment approaches [6].

Epigenetic therapies represent a growing frontier in gynecologic cancer management. Drugs targeting DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) are advancing in clinical development, with the potential to re-activate silenced tumor suppressor genes and enhance the efficacy of conventional treatments. Combination therapies are showing improved outcomes [7].

Genomic instability, a hallmark of cancer, is significantly exacerbated by epigenetic dysregulation in gynecologic cancers. Impaired DNA methylation and histone modification can compromise DNA repair mechanisms, leading to an accumulation of mutations and chromosomal aberrations. Understanding this critical interplay is essential for developing effective epigenetic interventions [8].

Epigenetic reprogramming plays a pivotal role in the development of resistance to established therapies in gynecologic cancers. Aberrant epigenetic changes can alter drug metabolism, signaling pathways, and cell survival mechanisms, diminishing the effectiveness of treatments. Strategies aimed at reversing these epigenetic alterations are being explored to overcome therapeutic resistance [9].

Finally, the heterogeneity of epigenetic landscapes across different subtypes of gynecologic cancers poses a challenge and an opportunity for personalized medicine. Recognizing and addressing this intra- and inter-tumor heterogeneity through tailored epigenetic therapies could significantly improve treatment efficacy and reduce toxicity, leading to better patient outcomes [10].

Conclusion

Epigenetic modifications, including DNA methylation and histone alterations, are critical drivers of gynecologic cancers, impacting gene silencing, oncogene activation, and genomic instability. These alterations influence the tumor microenvironment and the function of non-coding RNAs. Specific epigenetic biomarkers are emerging for early detection and risk stratification, with promising circulating tumor DNA profiles. Epigenetic therapies targeting DNMTs and HDACs are advancing, aiming to reawaken tumor suppressor genes and enhance conventional treatments. Understanding epigenetic reprogramming is crucial for overcoming treatment resistance and addressing tumor heterogeneity through personalized medicine approaches.

References

1. Swanzel NP, Karin MRvK, Celine CSvW. (2023) .Gynecologic Oncology 172:157.

   , ,

2. Anna MZK, Jian-Min Y, Elizabeth MS. (2022) .Cancer Research 82:7914-7930.

   , ,

3. Sarah EVJH, Annette MvdL, Anneke MWvdP. (2021) .Nature Reviews Clinical Oncology 18:519-534.

   , ,

4. Maria FLP, Rajesh KS, Sarah CJ. (2024) .Journal of the National Cancer Institute 116:335-348.

   , ,

5. Chen YL, Wei S, Jian Z. (2020) .Cell Death & Differentiation 27:1217-1230.

   , ,

6. Emily RC, David ML, Jonathan RR. (2023) .Clinical Cancer Research 29:2890-2905.

   , ,

7. Sarah PW, Thomas JG, Robert AW. (2022) .Annals of Oncology 33:1098-1110.

   , ,

8. Michael BC, Olivia KD, James WB. (2021) .Trends in Molecular Medicine 27:654-668.

   , ,

9. Jessica LW, Kevin AG, Laura MR. (2023) .Seminars in Oncology 50:114-125.

   , ,

10. David AC, Sophia LK, Daniel PL. (2022) .Gynecology and Minimally Invasive Therapy 11:45-52.

    , ,